← Back to Search

MRI-Ultrasound Fusion Device

MRI-ultrasound fusion device for Prostate Cancer

N/A
Waitlist Available
Led By Winston Barzell, MD
Research Sponsored by Focal Healthcare Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

The purpose of this study is to evaluate the effectiveness of Focal-Fusion Bx at detecting clinically significant prostate cancer in a standard clinical environment.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of biopsy cores positive for clinically significant cancer.
Secondary outcome measures
Number of men diagnosed with clinically significant and clinically insignificant cancer.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRI-ultrasound fusion deviceExperimental Treatment1 Intervention
Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging

Find a Location

Who is running the clinical trial?

Focal Healthcare Inc.Lead Sponsor
Winston Barzell, MDPrincipal Investigator21st Century Oncology, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025